Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)

John M. Kirkwood; Michele Del Vecchio; Jeffrey Weber; Christoph Hoeller; Jean Jacques Grob; Peter Mohr; Carmen Loquai; Caroline Dutriaux; Vanna Chiarion-Sileni; Jacek Mackiewicz; Piotr Rutkowski; Petr Arenberger; Gaelle Quereux; Tarek M. Meniawy; Paolo A. Ascierto; Alexander M. Menzies; Piyush Durani; Maurice Lobo; Federico Campigotto; Brian Gastman; Georgina V. Long

doi:10.1038/s41591-023-02775-w

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)

John M. Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian GastmanGeorgina V. Long

Internal Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Medicine, published online 16 October 2023. In the version of the article originally published, there was an error in the inset table in Extended Data Fig. 1a, where the text now reading “HR (95% CI)” previously read “Log-rank P”. This has now been corrected in the HTML and PDF versions of the article.

Original language	English
Pages (from-to)	906
Number of pages	1
Journal	Nature Medicine
Volume	30
Issue number	3
Early online date	4 Jan 2024
DOIs	https://doi.org/10.1038/s41591-023-02775-w
Publication status	Published - Mar 2024

Access to Document

10.1038/s41591-023-02775-wLicence: CC BY

Fingerprint

Dive into the research topics of 'Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)'. Together they form a unique fingerprint.

Cite this

Kirkwood, J. M., Del Vecchio, M., Weber, J., Hoeller, C., Grob, J. J., Mohr, P., Loquai, C., Dutriaux, C., Chiarion-Sileni, V., Mackiewicz, J., Rutkowski, P., Arenberger, P., Quereux, G., Meniawy, T. M., Ascierto, P. A., Menzies, A. M., Durani, P., Lobo, M., Campigotto, F., ... Long, G. V. (2024). Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2). Nature Medicine, 30(3), 906. https://doi.org/10.1038/s41591-023-02775-w

@article{21d3f931972344f4bfc082c63b790e08,

title = "Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)",

abstract = "Correction to: Nature Medicine, published online 16 October 2023. In the version of the article originally published, there was an error in the inset table in Extended Data Fig. 1a, where the text now reading “HR (95% CI)” previously read “Log-rank P”. This has now been corrected in the HTML and PDF versions of the article.",

author = "Kirkwood, {John M.} and {Del Vecchio}, Michele and Jeffrey Weber and Christoph Hoeller and Grob, {Jean Jacques} and Peter Mohr and Carmen Loquai and Caroline Dutriaux and Vanna Chiarion-Sileni and Jacek Mackiewicz and Piotr Rutkowski and Petr Arenberger and Gaelle Quereux and Meniawy, {Tarek M.} and Ascierto, {Paolo A.} and Menzies, {Alexander M.} and Piyush Durani and Maurice Lobo and Federico Campigotto and Brian Gastman and Long, {Georgina V.}",

note = "Publisher Copyright: {\textcopyright} 2024, The Author(s).",

year = "2024",

month = mar,

doi = "10.1038/s41591-023-02775-w",

language = "English",

volume = "30",

pages = "906",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group - Macmillan Publishers",

number = "3",

}

Kirkwood, JM, Del Vecchio, M, Weber, J, Hoeller, C, Grob, JJ, Mohr, P, Loquai, C, Dutriaux, C, Chiarion-Sileni, V, Mackiewicz, J, Rutkowski, P, Arenberger, P, Quereux, G, Meniawy, TM, Ascierto, PA, Menzies, AM, Durani, P, Lobo, M, Campigotto, F, Gastman, B & Long, GV 2024, 'Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)', Nature Medicine, vol. 30, no. 3, pp. 906. https://doi.org/10.1038/s41591-023-02775-w

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2). / Kirkwood, John M.; Del Vecchio, Michele; Weber, Jeffrey et al.
In: Nature Medicine, Vol. 30, No. 3, 03.2024, p. 906.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Author Correction

T2 - Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)

AU - Kirkwood, John M.

AU - Del Vecchio, Michele

AU - Weber, Jeffrey

AU - Hoeller, Christoph

AU - Grob, Jean Jacques

AU - Mohr, Peter

AU - Loquai, Carmen

AU - Dutriaux, Caroline

AU - Chiarion-Sileni, Vanna

AU - Mackiewicz, Jacek

AU - Rutkowski, Piotr

AU - Arenberger, Petr

AU - Quereux, Gaelle

AU - Meniawy, Tarek M.

AU - Ascierto, Paolo A.

AU - Menzies, Alexander M.

AU - Durani, Piyush

AU - Lobo, Maurice

AU - Campigotto, Federico

AU - Gastman, Brian

AU - Long, Georgina V.

PY - 2024/3

Y1 - 2024/3

N2 - Correction to: Nature Medicine, published online 16 October 2023. In the version of the article originally published, there was an error in the inset table in Extended Data Fig. 1a, where the text now reading “HR (95% CI)” previously read “Log-rank P”. This has now been corrected in the HTML and PDF versions of the article.

AB - Correction to: Nature Medicine, published online 16 October 2023. In the version of the article originally published, there was an error in the inset table in Extended Data Fig. 1a, where the text now reading “HR (95% CI)” previously read “Log-rank P”. This has now been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85181436524&partnerID=8YFLogxK

U2 - 10.1038/s41591-023-02775-w

DO - 10.1038/s41591-023-02775-w

M3 - Comment/debate

C2 - 38177857

AN - SCOPUS:85181436524

SN - 1078-8956

VL - 30

SP - 906

JO - Nature Medicine

JF - Nature Medicine

IS - 3

ER -

Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (Nature Medicine, (2023), 29, 11, (2835-2843), 10.1038/s41591-023-02583-2)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this